Opportunity Information: Apply for RFA RM 23 021
This funding opportunity, RFA-RM-23-021, is a National Institutes of Health (NIH) Notice of Funding Opportunity for a cooperative agreement (U24; clinical trial not allowed) to support Chemical Analysis Sites within the Molecular Transducers of Physical Activity Consortium (MoTrPAC). MoTrPAC is an NIH Common Fund effort focused on understanding the molecular changes triggered by physical activity and identifying the biological "transducers" that convert exercise and related stimuli into measurable molecular signals across tissues and organ systems. The core idea behind this FOA is to keep a specialized network of analysis sites operating in a coordinated way so that biospecimens collected through the consortium can continue to be processed using high-quality, standardized, and consortium-aligned omics pipelines, producing datasets that are consistent, comparable, and broadly useful to the research community.
The competition is limited, meaning it is not open to new applicants. Only organizations that were previously funded as MoTrPAC Chemical Analysis Sites under the earlier solicitations RFA-RM-15-010 and RFA-RM-15-011 are eligible to apply. The intent is continuity: NIH is essentially extending or renewing the consortium's chemical and omics analysis capacity by re-engaging established sites that already have the workflows, quality systems, staff expertise, and consortium experience needed to analyze MoTrPAC tissues efficiently and according to shared standards. Even though the source listing mentions small businesses under eligible applicants, the eligibility in the description clearly emphasizes the restricted pool of prior awardees, which is typical for limited competition FOAs that aim to maintain an existing program infrastructure rather than create new capacity.
Awardees funded through this FOA are expected to actively participate in MoTrPAC consortium activities, not simply run analyses independently. Because the funding mechanism is a cooperative agreement, NIH staff generally have substantial involvement in oversight, coordination, and milestone-driven progress, and recipients are expected to collaborate closely with other consortium components. The work supported centers on continued analysis of tissues collected from human participants undergoing a physical activity intervention, with an emphasis on omics-based characterization. In practice, that typically includes generating high-dimensional molecular datasets (for example, proteomics, metabolomics, lipidomics, or other chemical/omics readouts) from consortium biospecimens, following agreed-upon protocols for sample handling, measurement, normalization, and quality control.
A major deliverable under this FOA is the creation of well-curated datasets. This goes beyond producing raw instrument output and includes comprehensive quality assurance, annotation with appropriate metadata, harmonization with consortium data standards, and documentation sufficient for downstream interpretation. Awardees are also expected to contribute their finalized data products to a public consortium database so that the broader scientific community can access and reuse the results. In addition, these sites are not just data generators; they are expected to participate in consortium-wide data analysis efforts aimed at producing molecular "fingerprints" of physical activity. That consortium-level analysis is meant to identify candidate molecular transducers, meaning molecules, pathways, or molecular patterns that reliably reflect or mediate the biological effects of physical activity across time, intensity, and tissue context.
The FOA includes clear restrictions on foreign involvement. Non-U.S. (non-domestic) entities are not eligible to apply, non-U.S. components of U.S. organizations are not eligible, and foreign components as defined by the NIH Grants Policy Statement are not allowed. These restrictions narrow participation to domestic institutions and domestic project components, which simplifies compliance, data governance, and coordination for a large, multi-site effort built around standardized biospecimen and data workflows.
From the administrative details provided, the opportunity is categorized as discretionary funding and falls under the NIH health activity category, with CFDA number 93.310. The original application closing date was July 24, 2023, and the listed award ceiling is $350,000. The announcement was created on May 2, 2023. While the expected number of awards is not clearly specified in the provided excerpt, the limited competition nature implies a small set of possible awardees corresponding to the existing MoTrPAC Chemical Analysis Site awardees.
Overall, this FOA is designed to sustain and coordinate the consortium's chemical and omics analysis infrastructure so MoTrPAC can continue generating standardized, high-quality molecular datasets from human physical activity intervention tissues, rapidly sharing those datasets with the public, and collaboratively analyzing them to map the molecular signals that underlie the health effects of physical activity.Apply for RFA RM 23 021
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Limited Competition: Molecular Transducers of Physical Activity Chemical Analysis Sites (U24 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.310.
- This funding opportunity was created on 2023-05-02.
- Applicants must submit their applications by 2023-07-24. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the funding opportunity RFA-RM-23-021?
RFA-RM-23-021 is a National Institutes of Health (NIH) Notice of Funding Opportunity (NOFO) for a cooperative agreement (U24) to support Chemical Analysis Sites within the Molecular Transducers of Physical Activity Consortium (MoTrPAC). Clinical trials are not allowed under this opportunity.
What program or consortium does this opportunity support?
This opportunity supports MoTrPAC, an NIH Common Fund effort focused on understanding the molecular changes triggered by physical activity and identifying biological "transducers" that convert exercise-related stimuli into measurable molecular signals across tissues and organ systems.
What is the main purpose of this FOA?
The primary goal is to sustain a specialized, coordinated network of Chemical Analysis Sites so that MoTrPAC biospecimens can continue to be processed using standardized, high-quality, consortium-aligned omics pipelines. This is intended to produce datasets that are consistent, comparable, and broadly useful to the research community.
What is a "Chemical Analysis Site" in the MoTrPAC context?
Based on the information provided, Chemical Analysis Sites are specialized consortium sites responsible for generating chemical and omics measurements from MoTrPAC biospecimens using agreed-upon protocols, quality control processes, and data standards.
What NIH funding mechanism is used?
The mechanism is a cooperative agreement (U24). This implies active involvement by NIH staff in oversight, coordination, and milestone-driven progress, and it also implies that awardees are expected to collaborate closely with other MoTrPAC consortium components.
Are clinical trials allowed under this award?
No. The NOFO is explicitly described as "clinical trial not allowed."
Who is eligible to apply?
This is a limited competition opportunity and is not open to new applicants. Only organizations that were previously funded as MoTrPAC Chemical Analysis Sites under earlier solicitations RFA-RM-15-010 and RFA-RM-15-011 are eligible to apply.
Is this opportunity open to new organizations that have not been part of MoTrPAC?
No. The description emphasizes continuity and restricts eligibility to prior MoTrPAC Chemical Analysis Site awardees under RFA-RM-15-010 and RFA-RM-15-011.
Why is the competition limited?
The intent is to maintain and extend existing program infrastructure by re-engaging established sites that already have the workflows, quality systems, staff expertise, and consortium experience needed to analyze MoTrPAC tissues efficiently and according to shared standards.
Are foreign (non-U.S.) organizations eligible to apply?
No. Non-U.S. (non-domestic) entities are not eligible to apply under this FOA.
Can a U.S. organization include a non-U.S. component?
No. Non-U.S. components of U.S. organizations are not eligible, and foreign components (as defined by the NIH Grants Policy Statement) are not allowed.
What kinds of activities are awardees expected to perform?
Awardees are expected to conduct continued chemical and omics analysis of MoTrPAC biospecimens (tissues collected from human participants undergoing a physical activity intervention). They are also expected to participate in consortium activities rather than operating independently.
What types of data might be produced by these sites?
The FOA describes generating high-dimensional molecular datasets using omics-based characterization. Examples mentioned include proteomics, metabolomics, lipidomics, and other chemical/omics readouts.
What standards or protocols are expected for sample analysis?
Analyses are expected to follow agreed-upon, consortium-aligned protocols for sample handling, measurement, normalization, and quality control, with the goal of producing consistent and comparable datasets across sites.
What are the expected deliverables?
A major deliverable is well-curated datasets. This includes more than raw instrument output and is described as requiring comprehensive quality assurance, appropriate metadata annotation, harmonization with consortium data standards, and documentation sufficient for downstream interpretation.
Is public data sharing required?
Yes. Awardees are expected to contribute finalized data products to a public MoTrPAC consortium database so the broader scientific community can access and reuse the results.
Do awardees only generate data, or do they also help analyze it?
The opportunity expects sites to participate in consortium-wide data analysis efforts aimed at producing molecular "fingerprints" of physical activity and identifying candidate molecular transducers (molecules, pathways, or molecular patterns that reflect or mediate biological effects of physical activity).
What is meant by "molecular transducers" in this FOA?
In the description provided, molecular transducers are the molecules, pathways, or molecular patterns that convert exercise and related stimuli into measurable molecular signals across tissues and organ systems, and that may help explain the biological effects of physical activity.
What is the focus of the biospecimens being analyzed?
The work centers on analysis of tissues collected from human participants undergoing a physical activity intervention, with an emphasis on omics-based characterization.
Does NIH have an active role in the project?
Yes. Because this is a cooperative agreement, NIH staff generally have substantial involvement in oversight and coordination, and progress is described as milestone-driven.
What is the application due date listed in the provided information?
The original application closing date listed is July 24, 2023.
What is the award ceiling?
The listed award ceiling is $350,000.
When was the announcement created?
The announcement was created on May 2, 2023.
How many awards will be made?
The expected number of awards is not clearly specified in the provided excerpt. However, the limited competition structure implies a relatively small set of possible awardees corresponding to the existing MoTrPAC Chemical Analysis Site awardees.
How is this opportunity categorized administratively?
The opportunity is categorized as discretionary funding and falls under the NIH health activity category. The CFDA number listed is 93.310.
What is the overall outcome NIH is aiming for with this FOA?
The FOA is designed to sustain and coordinate MoTrPAC's chemical and omics analysis infrastructure so the consortium can continue generating standardized, high-quality molecular datasets from human physical activity intervention tissues, rapidly share those datasets publicly, and collaboratively analyze them to map molecular signals underlying the health effects of physical activity.
Browse more opportunities from the same category: Health
Next opportunity: Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Mining and Functional Validation (R01 Clinical Trial Not Allowed)
Previous opportunity: Using Multimodal Biomarkers to Differentially Diagnose ADRDs for Clinical Trials (U19 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA RM 23 021
Applicants also applied for:
Applicants who have applied for this opportunity (RFA RM 23 021) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition: Molecular Transducers of Physical Activity Bioinformatics Center (U24 Clinical Trial Not Allowed) Apply for RFA RM 23 020 Funding Number: RFA RM 23 020 Agency: National Institutes of Health Category: Health Funding Amount: $1,500,000 |
| AHRQ Health Services Research Dissertation Program (R36) Apply for PA 23 196 Funding Number: PA 23 196 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Center without Walls for PET Ligand Development for Alzheimer's disease-related dementias (ADRDs) (U19 - Clinical Trial Optional) Apply for RFA NS 24 011 Funding Number: RFA NS 24 011 Agency: National Institutes of Health Category: Health Funding Amount: $3,750,000 |
| Sex Differences in Radiation Research: Models, Underlying Pathways, Biomarkers of Injury, and Medical Countermeasure Responses (U01 Clinical Trial Not Allowed) Apply for RFA AI 23 024 Funding Number: RFA AI 23 024 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Predoctoral to Postdoctoral Fellow Transition Award (F99/K00 Clinical Trial Not Allowed) Apply for RFA OD 23 016 Funding Number: RFA OD 23 016 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Postdoctoral Mentored Career Development Award (K01 No Independent Clinical Trial Allowed) Apply for PAR 23 143 Funding Number: PAR 23 143 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Postdoctoral Mentored Career Development Award (K01 Clinical Trial Required) Apply for PAR 23 142 Funding Number: PAR 23 142 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Renewal of the Longevity Consortium (U19 Clinical Trial Not Allowed) Apply for RFA AG 24 017 Funding Number: RFA AG 24 017 Agency: National Institutes of Health Category: Health Funding Amount: $9,000,000 |
| Aging Research Dissertation Awards to Promote Diversity (R36 Clinical Trial Not Allowed) Apply for PAR 23 174 Funding Number: PAR 23 174 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed) Apply for PAR 23 177 Funding Number: PAR 23 177 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| HIV Prevention and Alcohol (R01 Clinical Trials Optional) Apply for PAS 23 173 Funding Number: PAS 23 173 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HIV Prevention and Alcohol (R34 Clinical Trials Optional) Apply for PAS 23 172 Funding Number: PAS 23 172 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Health Services Research (R01 Clinical Trial Optional) Apply for PAR 23 185 Funding Number: PAR 23 185 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Health Services Research (R34 Clinical Trial Optional) Apply for PAR 23 186 Funding Number: PAR 23 186 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Treatment and Recovery Research (R01 Clinical Trial Required) Apply for PAR 23 187 Funding Number: PAR 23 187 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Early-Stage Therapy Development for Alzheimer's Disease-Related Dementias (ADRD) (R61/R33 - Clinical Trial Not Allowed) Apply for RFA NS 24 010 Funding Number: RFA NS 24 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Treatment and Recovery Research (R34 Clinical Trial required) Apply for PAR 23 188 Funding Number: PAR 23 188 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Analyzing Early Events in TB and TB/HIV Infection for Interventional Targets (R01 Clinical Trial Not Allowed) Apply for RFA AI 23 029 Funding Number: RFA AI 23 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Collaborative Opportunities for Multidisciplinary, Bold, and Innovative Neuroscience (COMBINE) (RM1 Clinical Trial Optional) Apply for RFA NS 23 027 Funding Number: RFA NS 23 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding Gene-Environment Interactions in Brain Aging and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (U01 Clinical Trial Not Allowed) Apply for RFA AG 24 021 Funding Number: RFA AG 24 021 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA RM 23 021", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.